{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:26:48Z","timestamp":1790717208619,"version":"4.1.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jdcr.2022.08.038","type":"journal-article","created":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T12:15:18Z","timestamp":1661688918000},"page":"133-135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Treatment of cutaneous lupus with topical ruxolitinib cream"],"prefix":"10.1016","volume":"28","author":[{"given":"Jonathan J.","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia J.","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Vesely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdcr.2022.08.038_bib1","first-page":"81","article-title":"Cutaneous lupus erythematosus: current and future pathogenesis-directed therapies","volume":"93","author":"Little","year":"2020","journal-title":"Yale J Biol Med"},{"issue":"3","key":"10.1016\/j.jdcr.2022.08.038_bib2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/jdv.14053","article-title":"S2k guideline for treatment of cutaneous lupus erythematosus \u2013 guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)","volume":"31","author":"Kuhn","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"10.1016\/j.jdcr.2022.08.038_bib3","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41584-019-0272-0","article-title":"Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies","volume":"15","author":"Wenzel","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"10.1016\/j.jdcr.2022.08.038_bib4","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1177\/0961203316641771","article-title":"Advances in the treatment of cutaneous lupus erythematosus","volume":"25","author":"Kuhn","year":"2016","journal-title":"Lupus"},{"issue":"6","key":"10.1016\/j.jdcr.2022.08.038_bib5","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jid.2016.02.015","article-title":"JAK1\/2 inhibitor ruxolitinib controls a case of chilblain lupus erythematosus","volume":"136","author":"Wenzel","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"7","key":"10.1016\/j.jdcr.2022.08.038_bib6","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jamadermatol.2021.1198","article-title":"Use of tofacitinib, 2%, ointment for periorbital discoid lupus erythematosus","volume":"157","author":"Mazori","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"9","key":"10.1016\/j.jdcr.2022.08.038_bib7","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.jdcr.2022.08.038_bib8","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1038\/jid.2015.107","article-title":"Ruxolitinib attenuates cutaneous lupus development in a mouse lupus model","volume":"135","author":"Chan","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.jdcr.2022.08.038_bib9","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/art.39818","article-title":"Tofacitinib ameliorates murine lupus and its associated vascular dysfunction","volume":"69","author":"Furumoto","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jdcr.2022.08.038_bib10","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3389\/fimmu.2020.00344","article-title":"Selective janus kinase 1 inhibition is a promising therapeutic approach for lupus erythematosus skin lesions","volume":"11","author":"Fetter","year":"2020","journal-title":"Front Immunol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512622003964?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512622003964?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:24:48Z","timestamp":1762475088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512622003964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":10,"alternative-id":["S2352512622003964"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2022.08.038","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of cutaneous lupus with topical ruxolitinib cream","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2022.08.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}